Response to Office Action

REMARKS

After entry of this Response, Claims 1-4 and 7-61 are pending, with Claims 1, 7 and 10-

61 withdrawn, and Claims 2, 4 and 8 are amended. Applicants note that the species election

requirement directed to the method for expression determination has been withdrawn.

REJECTION OF CLAIMS 2-4, 8 AND 9 UNDER 35 U.S.C. § 112, SECOND PARAGRAPH

Claims 2-4 8, and 9 were rejected under 35 U.S.C. § 112, second paragraph, as being

indefinite for failing to particularly point out and distinctly claim the subject matter which

applicant regards as the invention. The Examiner objected to the use of the terms "under high

stringency conditions." Though Applicants traverse this finding, the currently pending claims no

longer recite this term, and thus, the rejection is moot. Applicants request the Examiner

withdraw the rejection.

REJECTION OF CLAIM 9 UNDER 35 U.S.C. § 112, FIRST PARAGRAPH

Claim 9 was rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the

written description requirement. Applicants traverse this rejection. In the specification, at least

at paragraph 56, where DNA array refers to "gene arrays, DNA chips, dot array Southerns, etc."

and "the DNA array will typically include one or a multiplicity of nucleic acid molecules derived

from SEQ. ID NO. 1 through SEQ. ID NO. 327". Applicants respectfully submit that the

specification, at least at paragraph 56, teaches using a DNA array to identify hybridizing nucleic

Serial No.: 09/973,994

Response to Office Action

acid sequences, which includes RNA sequences binding to DNA sequences bound in an array.

Applicants request that the Examiner withdraw the rejection.

REJECTION OF CLAIMS 2-4, 8 AND 9 UNDER 35 U.S.C. § 102(B)

Claims 2-3, and 8 were rejected under 35 U.S.C. § 102(b) as being anticipated by Dong,

et al. (March 1999), herein after "Dong 1999". Applicants respectfully traverse this rejection.

The Examiner stated that "Dong 1999 cites Dong et al (1996) for describing the

hybridizing conditions used by Dong 1999 in Northern blot hybridization assays. The method of

Dong et. al (Applicants' assumption is that the reference here and in the rest of the paragraph of

the rejection is to Dong 1999, though it is not clear which Dong reference is meant) comprises

detecting expression in a conifer embryo at least two RNA transcripts via Northern blot

analysis."

Applicants currently claimed invention is not taught by Dong 1999. At best, Dong 1999

discloses six cDNAs derived from a white spruce, (Picea glauca (Moench) Voss) embryo. This

disclosure does not provide an anticipatory teaching of Applicants' currently claimed invention,

because Dong 1999 merely teaches isolation of six cDNAs, but does not provide a teaching for

providing a method for staging conifer embryos with sequences that can provide a molecular

marker for a particular stage of development. Dong 1999 teaches six cDNA sequences that are

made from protein coding regions and these clones will cross hybridize with all members of the

gene family. Such cross hybridization does not provide for a specific marker and does not allow

for staging of embryos. Dong 1999 teaches that RNA transcripts related to pgEMB2 are

constitutively made throughout the embryo stages, which teaches that this clone is ineffective as

In re Application of: CAIRNEY, John et al.

Serial No.: 09/973,994 Response to Office Action

a marker. See page 860, second col. PgEMB8 is not found in zygotic embryos, and thus does

not function as a marker. All of the other clones are taught as members of gene families, which

means that cross-hybridization would occur and any correlations would be inaccurate and could

not be used to track particular gene activity or embryo staging. Applicants respectfully submit

that Dong 1999 does not provide an anticipatory teaching of the currently claimed invention and

request that the Examiner withdraw this rejection.

In re Application of: CAIRNEY, John et al.

Serial No.: 09/973,994 Response to Office Action

CONCLUSION

The foregoing is a complete Response to the Office Action mailed May 19, 2005.

Applicants respectfully submit that Claims 2-4, 8 and 9 are patentable, and early and favorable

consideration is solicited.

Applicants have included a check in the amount of \$510 for the three month extension of

time, but the Commissioner is hereby authorized to charge any other fees that may be required,

or to credit any overpayment, to Deposit Account No. 20-1507.

If the Examiner believes there are other issues that can be resolved by a telephone

interview, or that there are any informalities that remain in the application which may be

corrected by the Examiner's amendment, a telephone call to the undersigned attorney at (404)

885-3652 is respectfully solicited.

Respectfully submitted,

Mary Anthony Merchant, Ph.D.

Reg. No. 39,771

TROUTMAN SANDERS LLP

Bank of America Plaza

600 Peachtree Street, N.E.

Suite 5200

Atlanta, Georgia 30308-2216

Telephone: (404) 885-3652

Facsimile: (404) 962-6527